A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Adverse reactions; Registrational
  • Acronyms GLACIAL
  • Sponsors Genentech
  • Most Recent Events

    • 13 Jul 2016 Results of angioedema prevalence from three pivotal studies (ASTERIA I, ASTERIA II and GLACIAL) published in the Annals of Allergy, Asthma and Immunology
    • 16 Oct 2015 Results assessing response pattern of this and two other trials (ASTERIA-I and ASTERIA-II) published in the Journal of Allergy and Clinical Immunology
    • 24 Mar 2015 Post hoc pooled analysis; (ASTERIA-I, GLACIAL) symptoms and sleep co-relationship results presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top